31 related articles for article (PubMed ID: 20149658)
1. Novel tricyclic pyrazole BRAF inhibitors with imidazole or furan central scaffolds.
Niculescu-Duvaz D; Niculescu-Duvaz I; Suijkerbuijk BM; Ménard D; Zambon A; Nourry A; Davies L; Manne HA; Friedlos F; Ogilvie L; Hedley D; Takle AK; Wilson DM; Pons JF; Coulter T; Kirk R; Cantarino N; Whittaker S; Marais R; Springer CJ
Bioorg Med Chem; 2010 Sep; 18(18):6934-52. PubMed ID: 20667740
[TBL] [Abstract][Full Text] [Related]
2. Targeting CRAF kinase in anti-cancer therapy: progress and opportunities.
Wang P; Laster K; Jia X; Dong Z; Liu K
Mol Cancer; 2023 Dec; 22(1):208. PubMed ID: 38111008
[TBL] [Abstract][Full Text] [Related]
3. Challenges and Opportunities in the Crusade of BRAF Inhibitors: From 2002 to 2022.
Singh AK; Sonawane P; Kumar A; Singh H; Naumovich V; Pathak P; Grishina M; Khalilullah H; Jaremko M; Emwas AH; Verma A; Kumar P
ACS Omega; 2023 Aug; 8(31):27819-27844. PubMed ID: 37576670
[TBL] [Abstract][Full Text] [Related]
4. Imidazoles as potential anticancer agents.
Ali I; Lone MN; Aboul-Enein HY
Medchemcomm; 2017 Sep; 8(9):1742-1773. PubMed ID: 30108886
[TBL] [Abstract][Full Text] [Related]
5. Structure based design and syntheses of amino-1H-pyrazole amide derivatives as selective Raf kinase inhibitors in melanoma cells.
Kim MH; Kim M; Yu H; Kim H; Yoo KH; Sim T; Hah JM
Bioorg Med Chem; 2011 Mar; 19(6):1915-23. PubMed ID: 21353571
[TBL] [Abstract][Full Text] [Related]
6. 1,4-dihydropyrazolo[4,3-d]imidazole phenyl derivatives: a novel type II Raf kinase inhibitors.
Yu H; Jung Y; Kim H; Lee J; Oh CH; Yoo KH; Sim T; Hah JM
Bioorg Med Chem Lett; 2010 Jun; 20(12):3805-8. PubMed ID: 20466542
[TBL] [Abstract][Full Text] [Related]
7. Design, synthesis and biological evaluation of benzyl 2-(1H-imidazole-1-yl) pyrimidine analogues as selective and potent Raf inhibitors.
Kim M; Lee J; Jung K; Kim H; Aman W; Ryu JS; Hah JM
Bioorg Med Chem Lett; 2014 Aug; 24(15):3600-4. PubMed ID: 24878193
[TBL] [Abstract][Full Text] [Related]
8. Synthesis of pyrrolo[2,3-d]pyrimidine derivatives and their antiproliferative activity against melanoma cell line.
Jung MH; Kim H; Choi WK; El-Gamal MI; Park JH; Yoo KH; Sim TB; Lee SH; Baek D; Hah JM; Cho JH; Oh CH
Bioorg Med Chem Lett; 2009 Dec; 19(23):6538-43. PubMed ID: 19857963
[TBL] [Abstract][Full Text] [Related]
9. New imidazo[2,1-b]thiazole derivatives: synthesis, in vitro anticancer evaluation, and in silico studies.
Park JH; El-Gamal MI; Lee YS; Oh CH
Eur J Med Chem; 2011 Dec; 46(12):5769-77. PubMed ID: 22033063
[TBL] [Abstract][Full Text] [Related]
10. Discovery and initial SAR of pyrimidin-4-yl-1H-imidazole derivatives with antiproliferative activity against melanoma cell lines.
Lee J; Kim H; Yu H; Chung JY; Oh CH; Yoo KH; Sim T; Hah JM
Bioorg Med Chem Lett; 2010 Mar; 20(5):1573-7. PubMed ID: 20149658
[TBL] [Abstract][Full Text] [Related]
11. Role of Raf kinase in cancer: therapeutic potential of targeting the Raf/MEK/ERK signal transduction pathway.
Gollob JA; Wilhelm S; Carter C; Kelley SL
Semin Oncol; 2006 Aug; 33(4):392-406. PubMed ID: 16890795
[TBL] [Abstract][Full Text] [Related]
12. Recent progress in targeting the Raf/MEK/ERK pathway with inhibitors in cancer drug discovery.
Thompson N; Lyons J
Curr Opin Pharmacol; 2005 Aug; 5(4):350-6. PubMed ID: 15955734
[TBL] [Abstract][Full Text] [Related]
13.
; ; . PubMed ID:
[No Abstract] [Full Text] [Related]
14.
; ; . PubMed ID:
[No Abstract] [Full Text] [Related]
15.
; ; . PubMed ID:
[No Abstract] [Full Text] [Related]
16.
; ; . PubMed ID:
[No Abstract] [Full Text] [Related]
17.
; ; . PubMed ID:
[No Abstract] [Full Text] [Related]
18.
; ; . PubMed ID:
[No Abstract] [Full Text] [Related]
19.
; ; . PubMed ID:
[No Abstract] [Full Text] [Related]
20.
; ; . PubMed ID:
[No Abstract] [Full Text] [Related]
[Next] [New Search]
